Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,658 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, Fu L, Ma B, Ye S, Sun J, Lu W, Liu Z, Chen D, Cheng Z, Liu H, Zhang T, Zou J. Weng J, et al. Among authors: fu l. Diabetes Obes Metab. 2021 Aug;23(8):1754-1764. doi: 10.1111/dom.14389. Epub 2021 Apr 14. Diabetes Obes Metab. 2021. PMID: 33769656 Clinical Trial.
Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial.
Lu J, Fu L, Li Y, Geng J, Qin L, Li P, Zheng H, Sun Z, Li Y, Zhang L, Sun Y, Chen D, Qin G, Lu W, Guo Y, Zhang Y, Liu H, Zhang T, Zou J. Lu J, et al. Among authors: fu l. Diabetes Obes Metab. 2021 May;23(5):1111-1120. doi: 10.1111/dom.14314. Epub 2021 Jan 31. Diabetes Obes Metab. 2021. PMID: 33417292 Clinical Trial.
Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study.
Gu J, Zhang H, Xue Q, Wang L, Cheng Z, Zhang Y, Li Q, Yuan L, Li Y, Dong J, Huo Y, Tang X, Hu L, Wang X, Hua F, Shen L, Cheng J, Zhou H, Xu Y, Yang T, Wang C, Xu J, Shen J, Zhang Y, Zhang X, Hong D, Guan X, Xiao X, Wang G, Liu Y, Fu L, Chen J, Cheng X, Ding Y, Liu L, Yao Q, Zhang X, Li L, Zhang P, Deng C, Jiang C, You L, Wang K, Zhang S, Xiao J, Liu W, Du X, Shang X, Pan T, Lei C, Guo S, Zhang Z. Gu J, et al. Among authors: fu l. J Orthop Translat. 2022 Oct 29;38:117-125. doi: 10.1016/j.jot.2022.06.007. eCollection 2023 Jan. J Orthop Translat. 2022. PMID: 36381249 Free PMC article.
Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel study.
Ji L, Lu Y, Li Q, Fu L, Luo Y, Lei T, Li L, Ye S, Shi B, Li X, Meinicke T. Ji L, et al. Among authors: fu l. Diabetes Obes Metab. 2023 Jul;25(7):1839-1848. doi: 10.1111/dom.15041. Epub 2023 Mar 23. Diabetes Obes Metab. 2023. PMID: 36864540 Clinical Trial.
Antidiabetic and Antiobesity Effects of Artemether in db/db Mice.
Guo Y, Fu W, Xin Y, Bai J, Peng H, Fu L, Liu J, Li L, Ma Y, Jiang H. Guo Y, et al. Among authors: fu w, fu l. Biomed Res Int. 2018 May 13;2018:8639523. doi: 10.1155/2018/8639523. eCollection 2018. Biomed Res Int. 2018. PMID: 29862294 Free PMC article.
8,658 results